| Name | PQR620 |
| Description | PQR620 is a novel potent and selective, brain penetrant inhibitor of mTORC1/2. |
| In vitro | PQR620 is a potent and selective mTOR inhibitor with >1000-fold selectivity over PI3Kα in enzymatic binding assays. In A2058 melanoma cells, it inhibits protein kinase B (pSer473) and ribosomal protein S6 (pSer235/236) phosphorylation with IC50 values of 0.2 μM and 0.1 μM, respectively. PQR620 exhibits excellent selectivity across a broad range of kinases, receptor enzymes, and ion channels, and effectively prevents cancer cell growth in the NTRC 44 cancer cell line panel, achieving a 10log(IC50) of 2.86 (nM). |
| In vivo | PQR620 exhibits favorable physico-chemical properties, leading to good oral bioavailability and excellent brain penetration. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 6.4 mg/mL (14.37 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.24 mM), Sonication is recommended.
|
| Keywords | PQR-620 | PQR620 | PQR 620 | mTORC2 | mTORC1 | mTOR | Mammalian target of Rapamycin | Inhibitor | inhibit |
| Inhibitors Related | Stearamide | L-Leucine | 4-Vinylcyclohexene Dioxide | Resveratrol | N-Hydroxyphthalimide | L-Proline | Metformin | Methyl eugenol | Metformin hydrochloride | (E/Z)-10-Hydroxy-2-decenoic acid | Dihydromyricetin | Rapamycin |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Glycolysis Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | CNS-Penetrant Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
